Continuity Biosciences completed the acquisition of Focal Medical.

Continuity Biosciences, a developer of advanced drug delivery technologies, completed the acquisition of Focal Medical, a biotechnology company. Financial terms were not disclosed. "This is a transformative milestone for Continuity Biosciences. Focal Medical's approach to localized drug delivery aligns perfectly with our vision to improve bioavailability, reduce systemic exposure, and deliver better outcomes for patients. We are thrilled to bring this promising platform into our portfolio and into the clinic," Ramakrishna Venugopalan, Continuity Biosciences CEO.